English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/148814
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
DC FieldValueLanguage
dc.contributor.authorRedero, Mares_ES
dc.contributor.authorLópez-Causapé, Carlaes_ES
dc.contributor.authorBasas, Janaes_ES
dc.contributor.authorGavaldà, Joanes_ES
dc.contributor.authorOliver, Antonioes_ES
dc.contributor.authorBlázquez Gómez, Jesúses_ES
dc.contributor.authorPrieto Márquez, Ana Isabeles_ES
dc.date.accessioned2017-04-25T10:50:08Z-
dc.date.available2017-04-25T10:50:08Z-
dc.date.issued2016-09-
dc.identifier.citationXI Reunión del Grupo de Microbiología Molecular de la Sociedad Española de Microbiología (2016)es_ES
dc.identifier.urihttp://hdl.handle.net/10261/148814-
dc.descriptionPóster presentado en la XI Reunión del Grupo de Microbiología Molecular de la Sociedad Española de Microbiología (SEM), celebrada en Sevilla del 6 al 8 de septiembre de 2016.es_ES
dc.description.abstractThe recent appearance and dissemination of multidrug resistance (MDR) among bacteria have created a new threat for which traditional antibiotics offer little protection. After decades of neglect, the phage-therapy is beginning to be considered as a possible reemerging alternative. R-type pyocins are high-molecular-weight bacteriocins encoded in the chromosome of some bacterial species, such as Pseudomonas aeruginosa, supposedly to defend themselves against other strains of the same species. R-pyocins resemble the tails of lysogenic Myoviridae bacteriophages from which probably they evolved. The development of pulmonary MDR-P. aeruginosa infections is one of the most serious complications in the course of disease in patients with cystic fibrosis (CF), which often have very few antibiotic options . The analysis of approximately 200 P. aeruginosa clinical isolates shows that CF P. aeruginosa strains are hyper-susceptible to R-pyocins compared to isolates from other sources (bronchial aspirates, bloodstream, skin, sputum, abdominal, urine). The efficacy of R-pyocins in the eradication of P. aeruginosa infections has been tested through in vitro biofilms experiments and animal models. Treatments with R1, R2, or R5 pyocins prevent biofilm formation and also displayed a strong antimicrobial activity against established biofilms. In addiction, R-pyocins were also effective in ex vivo pig lung infection experiments, showing a 1000-fold decrease in the number of infecting bacteria. Moreover, administration of R2 pyocins in an in vivo murine model of ventilator-associated pneumonia (VAP) with a MDR clinical isolate (Pa1016) also showed a reduction of 100- fold in the number of bacteria recovered from lung after 24h of infection. Altogether, these results strongly suggest that R-pyocins could be a possible alternative to be used as antimicrobial agent alone or in combination with antibiotic therapy for the treatment of P. aeruginosa infections.es_ES
dc.language.isoenges_ES
dc.rightsclosedAccesses_ES
dc.titleKilling effect of R-pyocins on susceptible and multiresistant Pseudomonas aeruginosa clinical isolateses_ES
dc.typepóster de congresoes_ES
dc.description.peerreviewedNoes_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
Appears in Collections:(IBIS) Comunicaciones congresos
(CNB) Comunicaciones congresos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.